L I V E N
Pharma Limited.

+92-(3)-111-0-LIVEN
info@liven-pharma.com
www.liven-pharma.com
Site: 49-Km Lahore Multan Road, Pakistan.

CONFIRMATION OF CDC's NOMINEE HOLDING IN MEMBERS'/
CERTIFICATE HOLDERS' REGISTER

Chief Compliance Officer
Central Depository Company of Pakistan Limited
CDC House, 99-B, Block-B
S.M.C.H.S. Main Shahra-e-Faisal Karachi

Dear Sir,
In compliance with CDC Regulation No. 13.7.1, we are writing to confirm as follows:

Financial Year End	30/06/2025
Name of Auditor	Reanda Haroon Zakaria Aamir Salman Rizwan & Co., Chartered Accountants
Security Name	LIVEN PHARMA LIMITED
Security Symbol	LIVEN

	Note	**Number of Securities**
Balance at the end of period / year in the CDC's Nominee Holding in Members' / Certificate holders' Register	N-1	88,713,867
Balance of book entry security in the Central Depository Register at the end of period / year	N-2	88,713,867
Difference, if any		0

N-1: Movement in the CDC's Nominee Holding in Members' / Certificate holders' Register

	Number of Securities
Balance at the beginning of the year in the CDC's Nominee Holding in Members' / Certificate holders' Register	7,796,690
Add: Additions during the period / year	80,917,177
Less: Deletions during the period / year	0
Balance at the end of year / period in the CDC's Nominee Holding in Members' / Certificate holders' Register	88,713,867

N-2: Movement in the Central Depository Register

	Number of Securities
Balance at the beginning of the year in the Central Depository Register	7,796,690
Add: Additions during the period / year	80,917,177
Less: Deletions during the period / year	0
Balance at the end of year / period in the Central Depository Register	88,713,867

Reason for Difference and discrepancy (if any):
Regards,

Authorized Signatory (ies) / Company Secretary

This reconciliation would be stamped, signed and dated by the External Auditor here
01 OCT 2025

Liven Pharma Limited
Company Secretary

PNAC Accredited Company
PNAC Accredited Company
PNAC Accredited Company
cGMP CERTIFIED

REANDA

INDEPENDENT REASONABLE ASSURANCE REPORT ON STATEMENT OF FREE FLOAT OF SHARES

To the Chief Executive of the Liven Pharma Limited

1. Introduction

We have been engaged to perform a reasonable assurance engagement on the annexed Statement of Free Float of Shares (the 'Statement') of Liven Pharma Limited (the Company) as of September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025.

2. Applicable Criteria

The criteria against which the Statement is assessed is Regulation No. 5.7.2.(b)(ii) of Pakistan Stock Exchange Limited Regulations (PSX Regulations) which requires every listed company to submit directly to Pakistan Stock Exchange (PSX) an annual Free-Float Certificate duly verified by the auditor along with the annual audited accounts as prescribed under regulation 5.6.9.(a) of the PSX Regulations.

3. Management's Responsibility for the Statement

Management is responsible for the preparation of the Statement as of September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025 in accordance with the applicable criteria. This responsibility includes maintaining adequate records and internal controls as determined necessary to enable the preparation of the Statement such that it is free from material misstatement, whether due to fraud or error.

4. Our Independence and Quality Control

We have complied with the independence and other ethical requirements of the Code of Ethics for Chartered Accountants (Revised 2019) issued by the Institute of Chartered Accountants of Pakistan, which is founded on fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behavior.

The firm applies International Standard on Quality Management (ISQM) 1 "Quality Management for Firms that Perform Audits or Reviews of Financial Statements, or Other Assurance or Related Services Engagements", which requires the firm to design, implement and operate a system of quality management including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

5. Our responsibility and summary of the work performed

Our responsibility is to carry out an independent reasonable assurance engagement and to express an opinion as to whether the Statement is prepared in accordance with the applicable criteria, based on the procedures we have performed and the evidence we have obtained.

We conducted our reasonable assurance engagement in accordance with International Standard on Assurance Engagements 3000 (Revised), *'Assurance Engagements other than audits or reviews of historical financial statements'* (ISAE 3000) (Revised) issued by the International Auditing and Assurance Standards Board. That standard requires that we plan and perform this engagement to obtain reasonable level of assurance about whether the Statement is free from material misstatement.

A reasonable assurance engagement in accordance with ISAE 3000 (Revised) involves performing procedures to obtain evidence about the free float of shares and related information in the Statement. The nature, timing and extent of procedures selected depend on the practitioner's judgment, including the assessment of the risks of material misstatement, whether due to fraud or error, in the Statement. In making those risk assessments, we considered internal control relevant to Liven Pharma Limited's preparation of the Statement. A reasonable assurance engagement also includes assessing the applicable criteria used and significant estimates made by management, as well as, evaluating the overall presentation of the Statement.

We have carried out the procedures considered necessary for the purpose of providing reasonable assurance on the Statement. Our assurance procedures performed included verification of information in the Statement with the underlying data and record comprising of Central Depository Company statements, forms submitted by the Company with Securities & Exchange Commission of Pakistan relating to its pattern of shareholding and other related information. Verification that the computation of free float of shares is in accordance with the PSX regulation also forms part of our assurance procedures.

With respect to identification of associates of an individual as defined in section 2(ii)(a) of the Securities Act, 2015, we have obtained and relied on management's representations that are based on written declarations from individuals (i.e. directors, sponsors and senior management officers of the company) about their associates.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

6. Opinion

In our opinion, the Statement as of September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025 is prepared, in all material respects, in accordance with the PSX Regulations.

7. Restriction on use and distribution

This report is issued in relation to the requirements as stipulated under Regulation No 5.7.2.(b)(ii) of the PSX Regulations and is not to be used or distributed for any other purpose. This report is restricted to the facts stated herein and the attachments.

Reanda Haroon Zakaria Aamir Salman Rizwan & Co

Chartered Accountants
Place: Lahore
Date: October 01, 2025

L I V E N
Pharma Limited.

+92-(3)-111-0-LIVEN
info@liven-pharma.com
www.liven-pharma.com
Site: 49-Km Lahore Multan Road, Pakistan.

LIVEN PHARMA LIMITED
STATEMENT OF FREE FLOAT SHARES

		Quarter-1 30-09-24	Quarter-2 31-12-24	Quarter-3 31-03-25	Quarter-4 30-06-25
Total Outstanding Shares		12,123,700	93,040,367	93,040,367	93,040,367
	Less: Government Holdings	-	-	-	-
	Less: Shares held by Directors/Sponsors / Senior Management Officers and their associates	6,992,844	87,909,511	80,916,775	80,916,785
	Less: Shares in Physical Form	4,327,000	4,327,000	4,326,500	4,326,500
	Less: Shares held by Associate Companies / Group Companies (Cross holdings)	-	-	-	-
	Less: Shares issued under Employees Stock Option Schemes that cannot be sold in the open market in normal course.	-	-	-	-
	Less: Treasury Shares		-	-	-
	Less: Any other category that are barred from selling at the review date	-	-	-	-
Free Float		**803,856**	**803,856**	**7,797,092**	**7,797,082**

Basis of Preparation: This statement is prepared in accordance with the requirements of Regulation No. 5.7.2 (b)(ii) of Pakistan Stock Exchange Limited Regulation (PSX Regulations)

Liven Pharma Limited
Company Secretary

PNAC Accredited Company

PNAC Accredited Company

PNAC Accredited Company

cGMP CERTIFIED